Funder
Melanoma Institute Australia
National Computational Infrastructure
Nicholas and Helen Moore and Melanoma Institute Australia
National Health and Medical Research Council
Conquer Cancer Foundation
University of Sydney
Reference27 articles.
1. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study;Robert;Lancet Oncol,2019
2. Combined nivolumab and ipilimumab or monotherapy in untreated Melanoma;Larkin;N Engl J Med,2015
3. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma;Wolchok;J Clin Oncol,2022
4. Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma;Robert;J Clin Oncol,2023
5. Mutations associated with acquired resistance to PD-1 blockade in melanoma;Zaretsky;N Engl J Med,2016
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献